Quarterly report [Sections 13 or 15(d)]

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

v3.26.3
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)        
Revenues, net $ (40,348) $ 213,910 $ 126,690 $ 527,047
Operating expenses:        
Cost of goods sold 2,625 0 172,776 0
Research and development 746,064 1,004,661 1,810,781 1,463,440
Selling, general and administrative 601,248 902,594 2,078,753 3,011,998
Impairment of intellectual property 0 0 6,374 0
Depreciation and amortization 8,474 71,987 29,503 168,807
Total operating expenses 1,358,411 1,979,242 4,098,187 4,644,245
Loss from operations (1,398,759) (1,765,332) (3,971,497) (4,117,198)
Other income (expenses):        
Interest expense - related parties (143,231) (167,520) (417,276) (492,019)
Interest expense, net (37,377) (60,495) (98,466) (184,664)
Loss on settlement of debt 0 0 (147,000) (187,514)
Grant income 768,674 1,305,349 1,810,748 1,873,598
Change in fair value of upfront purchase price liability 0 (1,785) 0 (6,679)
Change in fair value of royalty liability 0 (180,257) 0 (148,933)
Other miscellaneous income 20 58,708 20 223,037
Total other income 588,086 954,000 1,148,026 1,076,826
Loss before provision for income taxes (810,673) (811,332) (2,823,471) (3,040,372)
Income taxes 0 0 0 0
Net loss (810,673) (811,332) (2,823,471) (3,040,372)
Non-controlling interest 13,539 (35,759) 115,727 118,456
Net loss attributable to BioCorRx Inc. $ (797,134) $ (847,091) $ (2,707,744) $ (2,921,916)
Net loss per common share, basic and diluted $ (0.03) $ (0.05) $ (0.10) $ (0.17)
Weighted average number of common shares outstanding, basic and diluted 30,100,460 18,559,428 28,323,034 16,901,306